Across TCGA pan-cancer cohorts, PDE4B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PDE4B data layer compared with 22 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PDE4B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDE4B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC are the cancer types where PDE4B mass-spec protein most reproducibly stratifies survival.